LOR-253 is a small molecule compound that has shown selective and potent antitumor activity in a variety of human cancers, including non-small cell and has an excellent therapeutic window due to its low toxicity. LOR-253 is an inhibitor of the first class of targeted cancer-Responsive Metal transcription factor 1 (MTF-1). The mode of action of LOR-253 involves the downregulation of cyclin D1, an important regulator of cell cycle progression and cell proliferation, and decreased the expression of genes involved in tumor hypoxia (low oxygen) and angiogenesis. Increased angiogenesis and alterations in the regulation of cyclin D1 has been linked to cancer.The clinical batch LOR-253 is designed in full compliance with current Good Manufacturing Practices (GMP) and should be used in a first study in humans of LOR-253. An investigational new drug (IND) for LOR-253 is being finalized for submission to the FDA for a Phase I dose escalation in some solid tumors.
Lorus Therapeutics Inc. (TSX: LOR) (“Lorus”), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and management technologies, announced that production of the first clinical batch of its new cancer drug LOR Candidate -253 has been successfully completed.
“The production of our first line of clinical batches of cGMP LOR-253 is an important step in the development of this new compound, and demonstrates our commitment to advance LOR-253 to the clinic,” said Aiping Young, President and CEO Lorus.